Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Boroumand Noughabi, Samaneh ^a,b   Sima, Hamid R ^a   Ghaffarzadehgan, Kamran ^c   Jafarzadeh, Mostafa ^b,d   Raziee, Hamid R ^c   Hosseinnezhad, Hanieh ^b,d   Moaven, Omeed ^b   Rajabi Mashhadi, Mohammad T ^e   Azarian, Amir A ^b   Mashhadinejad, Mojtaba ^b   Tavakkol Afshari, Jalil ^f  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; OPIATE; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CIGARETTE SMOKING; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTRECTOMY; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; OPIATE ADDICTION; PRECANCER; SOCIAL STATUS; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; ADENOCARCINOMA; BLOOD; CANCER STAGING; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; IRAN; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD95; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; GASTRECTOMY; HUMANS; IRAN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77953279160     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-275     Document Type: Article

References (37)

1. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005, 241(1):27-39. 1356843, 15621988.
2. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009, 20(3):556-563. 10.1093/annonc/mdn642, 19073863.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
4. Reed JC. Apoptosis and cancer. Cancer medicine 2003, 41-52. Hamilton: BC Decker, Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, 6.
5. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104(4):487-501. 10.1016/S0092-8674(01)00237-9, 11239407.
6. Krammer PH. CD95's deadly mission in the immune system. Nature 2000, 407(6805):789-795. 10.1038/35037728, 11048730.
7. Ju ST, Panka DJ, Cui H, Ettinger R, el-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995, 373(6513):444-448. 10.1038/373444a0, 7530337.
8. Li-Weber M, Krammer PH. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin Immunol 2003, 15(3):145-157. 10.1016/S1044-5323(03)00030-7, 14563113.
9. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002, 71(6):907-920.
10. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995, 154(6):2706-2713.
11. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994, 263(5154):1759-1762. 10.1126/science.7510905, 7510905.
12. Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H, Aozasa K. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000, 82(8):1446-1452. 2363379, 10780525.
13. Bebenek M, Dus D, Kozlak J. Fas expression in primary breast cancer is related to neoplastic infiltration of perilymphatic fat. Adv Med Sci 2008, 53(1):49-53. 10.2478/v10039-008-0015-y, 18614439.
14. Kamihira S, Yamada Y, Tomonaga M, Sugahara K, Tsuruda K. Discrepant expression of membrane and soluble isoforms of Fas (CD95/APO-1) in adult T-cell leukaemia: soluble Fas isoform is an independent risk factor for prognosis. Br J Haematol 1999, 107(4):851-860. 10.1046/j.1365-2141.1999.01792.x, 10606894.
15. Tamakoshi A, Nakachi K, Ito Y, Lin Y, Yagyu K, Kikuchi S, Watanabe Y, Inaba Y, Tajima K. Soluble Fas level and cancer mortality: findings from a nested case-control study within a large-scale prospective study. Int J Cancer 2008, 123(8):1913-1916. 10.1002/ijc.23731, 18688865.
16. Bennett MW, O'connell J, O'sullivan GC, Roche D, Brady C, Kelly J, Collins JK, Shanahan F. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 1999, 44(2):156-162. 1727385, 9895372.
17. Li Z, Wang Z, Zhao Z, Zhang Y, Ke Y. [Expression of Fas, FasL and IFN-gamma in gastric cancer]. Beijing Da Xue Xue Bao 2003, 35(4):386-389.
18. Zheng HC, Sun JM, Wei ZL, Yang XF, Zhang YC, Xin Y. Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol 2003, 9(7):1415-1420.
19. Ohno S, Tachibana M, Shibakita M, Dhar DK, Yoshimura H, Kinugasa S, Kubota H, Masunaga R, Nagasue N. Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer. Ann Surg Oncol 2000, 7(10):750-757. 10.1007/s10434-000-0750-1, 11129423.
20. Ichikura T, Majima T, Uchida T, Okura E, Ogawa T, Mochizuki H. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. Oncol Rep 2001, 8(2):311-314.
21. Liang QL, Pan DC, Yin ZM, Liu GX, Yang Q, Xie JR, Cai LZ, Fu YW. [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma]. Ai Zheng 2002, 21(2):174-176.
22. Tsutsumi S, Kuwano H, Shimura T, Morinaga N, Mochiki E, Asao T. Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 2000, 89(12):2560-2564. 10.1002/1097-0142(20001215)89:12<2560::AID-CNCR7>3.0.CO;2-Q, 11135216.
23. Yatsuya H, Toyoshima H, Tamakoshi K, Tamakoshi A, Kondo T, Hayakawa N, Sakata K, Kikuchi S, Hoshiyama Y, Fujino Y, Mizoue T, Tokui N, Yoshimura T. Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor beta-1, soluble fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC Study. J Epidemiol 2005, 15(Suppl 2):S120-125. 10.2188/jea.15.S120, 16127223.
24. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20(10):1161-1181. 10.1097/00000478-199610000-00001, 8827022.
25. Bremer E, de Bruyn M, Wajant H, Helfrich W. Targeted cancer immunotherapy using ligands of the tumor necrosis factor super-family. Curr Drug Targets 2009, 10(2):94-103. 10.2174/138945009787354593, 19199904.
26. Rikhof B, van der Graaf WT, Meijer C, Le PT, Meersma GJ, de Jong S, Fletcher JA, Suurmeijer AJ. Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br J Cancer 2008, 99(10):1600-1606. 10.1038/sj.bjc.6604736, 2584951, 18941456.
27. Li H, Liu N, Guo L, Li JW, Liu J. Frequent expression of soluble Fas and Fas ligand in Chinese stomach cancer and its preneoplastic lesions. Int J Mol Med 2000, 5(5):473-476.
28. Bellone G, Smirne C, Carbone A, Mareschi K, Dughera L, Farina EC, Alabiso O, Valente G, Emanuelli G, Rodeck U. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. clin Cancer Res 2000, 6(6):2448-2455.
29. Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 2001, 92(2):287-293. 10.1002/1097-0142(20010715)92:2<287::AID-CNCR1321>3.0.CO;2-4, 11466681.
30. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. Fas ligand in human serum. Nat Med 1996, 2(3):317-322. 10.1038/nm0396-317, 8612231.
31. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002, 8(8):2553-2562.
32. Yoshikawa T, Saito H, Osaki T, Matsumoto S, Tsujitani S, Ikeguchi M. Elevated Fas expression is related to increased apoptosis of circulating CD8+ T cell in patients with gastric cancer. J Surg Res 2008, 148(2):143-151. 10.1016/j.jss.2007.07.011, 18561948.
33. Kim R, Emi M, Tanabe K, Arihiro K. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 2006, 7(12):1006-1016. 10.1016/S1470-2045(06)70975-5, 17138222.
34. Kuo WH, Chen JH, Lin HH, Chen BC, Hsu JD, Wang CJ. Induction of apoptosis in the lung tissue from rats exposed to cigarette smoke involves p38/JNK MAPK pathway. Chem Biol Interact 2005, 155(1-2):31-42. 10.1016/j.cbi.2005.04.008, 15970277.
35. Park JW, Kim HP, Lee SJ, Wang X, Wang Y, Ifedigbo E, Watkins SC, Ohba M, Ryter SW, Vyas YM, Choi AM. Protein kinase C alpha and zeta differentially regulate death-inducing signaling complex formation in cigarette smoke extract-induced apoptosis. J Immunol 2008, 180(7):4668-4678.
36. Imirzalioglu P, Uckan S, Alaaddinoglu EE, Haberal A, Uckan D. Cigarette smoking and apoptosis. J Periodontol 2005, 76(5):737-739. 10.1902/jop.2005.76.5.737, 15898934.
37. Sarafian TA, Tashkin DP, Roth MD. Marijuana smoke and Delta(9)-tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. Toxicol Appl Pharmacol 2001, 174(3):264-272. 10.1006/taap.2001.9224, 11485387.